White Paper

Keys To Success With Direct-To-Patient Clinical Trials

patient with prescription iStock-1253815432

Drug development is a risky endeavor that is expensive, complex, and lengthy. A significant portion of resources earmarked for drug development programs are consumed by screening, recruiting, enrolling, engaging, monitoring, and retaining patients in clinical trials. The pharmaceutical industry is continually exploring novel trial designs and methods that may alleviate the high costs and shorten study times, which can ultimately expedite new medicines to market.

In clinical trials, the Direct-to-Patient (DtP) model allows for study medications1 to be received and administered in a patient’s home rather than a clinical site. The DtP drug supply model has gained momentum in recent years and continues to evolve since it can confer valuable benefits to sponsors and patients.

This intention of this paper is two-fold:

  1. Provide a brief overview of factors that drive the rapidly evolving clinical trial design landscape, and
  2. Demonstrate how DtP trials can solve some of the difficulties facing drug sponsors today, including common pitfalls to consider when embarking on a DtP trial.
VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Medidata, a Dassault Systemes company